In summary, miR-33b acts as a tumor suppressor, inhibiting oncogenesis and targeting ovarian cancer lipid metabolism by downregulating TAK1/FASN/CPT1A/NF-κB signaling. This evidence concerns the gene FASN and ovarian cancer.